EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Fibrin(ogen)-derived peptide B beta 30-43 increases coronary blood flow in the anesthetized dog



Fibrin(ogen)-derived peptide B beta 30-43 increases coronary blood flow in the anesthetized dog



Thrombosis Research 39(2): 223-229



The hemodynamic effects of intracoronary administration of a fibrin (ogen)-derived peptide B beta 30-43 (Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Ala) were evaluated in open-chest anesthetized dogs. Coronary blood flow (CBF) increased and coronary vascular resistance (CVR) decreased with intracoronary administration of peptide B beta 30-43. These changes were dependent on the amount of the peptide B beta 30-43 administered. There were no significant effects of peptide B beta 30-43 on aortic & left ventricular end-diastolic pressures. Plasma 6-keto-PGF1 alpha (stable hydrolysis product of PGI2) concentrations increased in coronary sinus blood samples in conjunction with increase in CBF. Intravenous administration of indomethacin (5 mg/kg) inhibited the release of PGI2 and almost completely abolished the effects of the fibrin(ogen)-derived peptide on CBF. This study suggests that this fibrin (ogen)-derived peptide has potent effects on the coronary vascular bed of the dog, and that these effects are in large part mediated through PGI2 release. These coronary hemodynamic effects of fibrin(ogen)-derived products may have important autoregulatory effects in atheromatous coronary circulation, wherein thrombi may form spontaneously.

(PDF 0-2 workdays service: $29.90)

Accession: 040142525

Download citation: RISBibTeXText

PMID: 3895564



Related references

Peptide 6a a fibrin ogen degradation products increases coronary blood flow. American Journal of Physiology 249(3 PART 2): H457-H462, 1985

Fibrin(ogen) degradation product peptide 6A increases femoral artery blood flow in dogs. Acta Physiologica Scandinavica 142(3): 339-344, 1991

Fibrin (ogen)-derived peptide B beta 30-43 is a sensitive marker of activated neutrophils during fibrinolytic-treated acute myocardial infarction in man. American Heart Journal 124(4): 841-845, 1992

Intracoronary genistein acutely increases coronary blood flow in anesthetized pigs through beta-adrenergic mediated nitric oxide release and estrogenic receptors. Endocrinology 149(5): 2678-2687, 2008

Pulmonary vascular effects of a fibrin(ogen)-derived vasoactive peptide. Thrombosis Research 42(6): 783-788, 1986

Effect of a fibrin(ogen)-derived vasoactive peptide on polymorphonuclear leukocyte emigration. Thrombosis Research 37(1): 85-89, 1985

A peptide derived from fibrin(ogen) inhibits angiotensin converting enzyme and potentiates the effects of bradykinin. Thrombosis Research 23(4-5): 465-470, 1981

Fibrin(ogen) peptide B beta 15-42 inhibits platelet aggregation and fibrinogen binding to activated platelets. Biochemistry 27(16): 6121-6126, 1988

Replacement of L-Lys by D-Lys(NH2) in peptide Ala-Arg-Pro-Ala-Lys (peptide 6A) increases its coronary blood flow-promoting properties. Journal of Cardiovascular Pharmacology 23(1): 103-106, 1994

Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets. Circulation 90(2): 988-996, 1994

Intracoronary melatonin increases coronary blood flow and cardiac function through β-adrenoreceptors, MT1/MT2 receptors, and nitric oxide in anesthetized pigs. Journal of Pineal Research 51(2): 246-257, 2011

Thrombin receptor activating peptide alters coronary blood flow, left ventricular function and ECG in anesthetized dogs. FASEB Journal 9(3): A57, 1995